Thermo Fisher Scientific said this week it has acquired the exclusive rights from diagnostics firm Nephromics to use placental growth factor protein as a biomarker for the diagnosis of preeclampsia and eclampsia.

The company will develop PLGF as an immunoassay on its Kryptor platform, complementing its existing prenatal screening products, which include assays for PAPP-A, free βhCG, and AFP. It said it plans to launch the test in the first quarter of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.